CCT2 and plasma cell myeloma: A predictive model developed by Mohamad and others, based on five genes including CKS1B, CCT2, PRKDC, NONO, and UBE2A, successfully predicted the prognosis of patients with multiple myeloma and has been validated in several independent datasets.